RNAアプタマーが凝固因子IXaの可逆抗体として作用する
Christopher P Rusconi1, Elizabeth Scardino, Juliana Layzer
1Department of Surgery, Program in Combinatorial Therapeutics, Duke University Medical Center, Durham, North Carolina 27710, USA. c.rusconi@cgt.duke.edu
Nature
|September 6, 2002
まとめ
研究者らは,核酸を使用してより安全な抗凝固剤を作成するための新しい戦略を開発しました. アプタマーは抗凝固剤として作用し,補完的なオリゴヌクレオチドは効果的な抗薬として作用し,薬物作用の正確な制御を可能にします.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 薬理学 薬理学とは
背景:
- 治療薬,特に抗凝固剤は,出血などの副作用のリスクを伴う.
- ヘパリンは,制限にもかかわらず,制御可能な解毒剤であるプロタミンのために広く使用されています.
- 薬物対抗剤のペアの設計のための一般化可能な戦略は,現在欠けている.
研究 の 目的:
- 核酸特性を用いて薬物-解毒剤ペアの合理的な設計を調査する.
- 特定の解毒剤によって制御可能な新しい抗凝固剤を開発する.
主な方法:
- 設計されたタンパク質結合オリゴヌクレオチド (アプタマー) が凝固因子IXaを標的とする.
- 合成された補完性オリゴヌクレオチドは,アプタマー結合抗薬として機能する.
- テストされた抗凝固剤の活性と,ヒトの血における抗毒剤による逆転.
主要な成果:
- 因子IXaを標的とするアプタマーには強力な抗凝固作用が示された.
- 補完的なオリゴヌクレオチドは,アプタメルの抗凝固効果を効率的に逆転させました.
- 薬剤対抗剤システムは,健康なボランティアとヘパリン不耐症患者の血で有効であることが証明されました.
結論:
- 核酸ベースの薬物-解毒剤ペアの設計のための一般化可能な戦略が確立されています.
- このアプローチにより,より安全で調節可能な抗凝固剤の治療薬の開発が可能になります.
- これは,抗凝固を超えて制御可能な薬物システムを構築するための道を開きます.
関連する概念動画
RNA Interference
24.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.3K
Experimental RNAi
6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Drug-Receptor Interaction: Antagonist
4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Combined Effects of Drugs: Antagonism
11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K


